company background image
524632 logo

Shukra Pharmaceuticals BSE:524632 Stock Report

Last Price

₹206.65

Market Cap

₹9.0b

7D

-5.9%

1Y

342.2%

Updated

15 Feb, 2025

Data

Company Financials

Shukra Pharmaceuticals Limited

BSE:524632 Stock Report

Market Cap: ₹9.0b

524632 Stock Overview

Develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. More details

524632 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends3/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Shukra Pharmaceuticals Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shukra Pharmaceuticals
Historical stock prices
Current Share Price₹206.65
52 Week High₹238.15
52 Week Low₹48.78
Beta0.27
1 Month Change3.56%
3 Month Change213.25%
1 Year Change342.15%
3 Year Change983.36%
5 Year Change1,538.45%
Change since IPO429.87%

Recent News & Updates

Recent updates

Shareholder Returns

524632IN PharmaceuticalsIN Market
7D-5.9%-7.5%-5.6%
1Y342.2%9.0%-0.9%

Return vs Industry: 524632 exceeded the Indian Pharmaceuticals industry which returned 9% over the past year.

Return vs Market: 524632 exceeded the Indian Market which returned -0.9% over the past year.

Price Volatility

Is 524632's price volatile compared to industry and market?
524632 volatility
524632 Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement6.4%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market4.4%

Stable Share Price: 524632 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 524632's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993182Dakshesh Shahwww.shukrapharmaceuticals.com

Shukra Pharmaceuticals Limited develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016.

Shukra Pharmaceuticals Limited Fundamentals Summary

How do Shukra Pharmaceuticals's earnings and revenue compare to its market cap?
524632 fundamental statistics
Market cap₹9.05b
Earnings (TTM)₹81.75m
Revenue (TTM)₹333.97m

110.7x

P/E Ratio

27.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524632 income statement (TTM)
Revenue₹333.97m
Cost of Revenue₹80.21m
Gross Profit₹253.76m
Other Expenses₹172.02m
Earnings₹81.75m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.87
Gross Margin75.98%
Net Profit Margin24.48%
Debt/Equity Ratio5.0%

How did 524632 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

24%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 12:29
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shukra Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.